New Eli Lilly weight loss drug has dramatic effects in clinical trial
Eli Lilly's new weight loss drug, retatrutide, has shown significant results in clinical trials, enabling patients to achieve weight loss levels comparable to bariatric surgery. Participants lost an average of 28% of their body weight over 18 months, with nearly half losing at least 30%. The drug's unique formulation may help users maintain muscle mass better than other GLP-1 medications.
- ▪Retatrutide helped patients lose an average of 28% of their body weight in a phase 3 clinical trial.
- ▪Nearly half of the participants lost at least 30% of their body weight, similar to gastric bypass surgery results.
- ▪Eli Lilly plans to seek FDA approval for retatrutide by the end of the year, depending on the outcomes of two late-stage trials.
Opening excerpt (first ~120 words) tap to expand
An experimental anti-obesity injection helped patients reach new levels of weight loss previously only achievable through bariatric surgery, according to new data from the pharmaceutical giant Eli Lilly. The new medication, retatrutide, appears to be the most powerful medication of its kind in a wave of injections and pills that have transformed obesity and diabetes management in recent years. Recommended Stories Surgeon general advisory raises concern about screen time for children and teenagers RFK Jr.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Washington Examiner.
Discussion
0 commentsMore from Washington Examiner
